Genetically engineered mouse models of pancreatic cancer

Cancer Journal (United States)

Volumn 18, Issue 6, 2012, Pages 502-510

  Westphalen, Christoph Benedikt ^a,b   Olive, Kenneth P ^a,b  

^a Division of Digestive and Liver Diseases   (United States)

^b New York Presbyterian Morgan Stanley Children's Hospital   (United States)

Author keywords

genetically engineered mouse models; Pancreatic cancer; preclinical testing; transgenic

Indexed keywords

ANTINEOPLASTIC AGENT; CRE RECOMBINASE; CYCLIN DEPENDENT KINASE INHIBITOR 2A; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYALURONIDASE; MITOGEN ACTIVATED PROTEIN KINASE; PACLITAXEL; PEGPH 20; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P16; RAF PROTEIN; REPARIXIN; SARIDEGIB; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR;

CANCER GROWTH; CANCER INVASION; CANCER MODEL; CANCER SURVIVAL; CARCINOGENESIS; CD8+ T LYMPHOCYTE; EPITHELIUM CELL; GAIN OF FUNCTION MUTATION; GENETIC ENGINEERING; HUMAN; METASTASIS; NONHUMAN; ONCOGENE K RAS; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE;

ANIMALS; CARCINOMA, PANCREATIC DUCTAL; DISEASE MODELS, ANIMAL; GENETIC ENGINEERING; HUMANS; MICE; MICE, TRANSGENIC; PANCREATIC NEOPLASMS;

EID: 84871196163     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e31827ab4c4     Document Type: Review

References (94)

1. Hidalgo M. Pancreatic cancer. N Engl J Med. 2010;362:1605-1617.
2. Vincent A, Herman J, Schulick R, et al. Pancreatic cancer. Lancet. 2011;378:607-620.
3. Jones S, Zhang X, Parsons DW, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 2008;321:1801-1806.
4. Maitra A, Adsay NV, Argani P, et al. Multicomponent analysis of the pancreatic adenocarcinoma progression model using a pancreatic intra-epithelial neoplasia tissue microarray. Mod Pathol. 2003;16:902-912.
5. Neesse A, Michl P, Frese KK, et al. Stromal biology and therapy in pancreatic cancer. Gut. 2010;6:861-868.
6. Perez-Mancera PA, Guerra C, Barbacid M, et al. What we have learned about pancreatic cancer from mouse models. Gastroenterology. 2012;142:1079-1092.
7. Corbett TH, Roberts BJ, Leopold WR, et al. Induction and chemother-apeutic response of two transplantable ductal adenocarcinomas of the pancreas in C57BL/6 mice. Cancer Res. 1984;44:717-726.
8. Longnecker DS. Lesions induced in rodent pancreas by azaserine and other pancreatic carcinogens. Environ Health Perspect. 1984;56: 245-251.
9. Jackson EL, Willis N, Mercer K, et al. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev. 2001;15:3243-3248.
10. Johnson L, Mercer K, Greenbaum D, et al. Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature. 2001; 410:1111-1116.
11. McGrath JP, Capon DJ, Goeddel DV, et al. Comparative biochemical properties of normal and activated human ras p21 protein. Nature. 1984;310:644-649.
12. Sweet RW, Yokoyama S, Kamata T, et al. The product of ras is a GTPase and the T24 oncogenic mutant is deficient in this activity. Nature. 1984;311:273-275.
13. Gibbs JB, Sigal IS, Poe M, et al. Intrinsic GTPase activity distinguishes normal and oncogenic ras p21 molecules. Proc Natl Acad Sci USA. 1984;81:5704-5708.
14. Der CJ, Finkel T, Cooper GM. Biological and biochemical properties of human rasH genes mutated at codon 61. Cell. 1986;44:167-176.
15. Hingorani SR, Jacobetz MA, Robertson GP, et al. Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Res. 2003;63:5198-5202.
16. Aguirre AJ, Bardeesy N, Sinha M, et al. Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocar-cinoma. Genes Dev. 2003;17:3112-3126.
17. Pan FC, Wright C. Pancreas organogenesis: from bud to plexus to gland. Dev Dyn. 2011;240:530-565.
18. Hingorani SR, Petricoin EF, Maitra A, et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell. 2003;4:437-450.
19. + cells are islet progenitors and are distinct from duct progenitors. Development. 2002;129:2447-2457.
20. Kawaguchi Y, Cooper B, Gannon M, et al. The role of the transcrip-tional regulator Ptf1a in converting intestinal to pancreatic progenitors. Nat Genet. 2002;32:128-134.
21. Hingorani SR, Wang L, Multani AS, et al. Trp53R172H and Kras-G12D cooperate to promote chromosomal instability and widely meta-static pancreatic ductal adenocarcinoma in mice. Cancer Cell. 2005; 7:469-483.
22. Bardeesy N, Cheng K-H, Berger JH, et al. Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer. Genes Dev 2006;20:3130-3146.
23. Morton JP, Timpson P, Karim SA, et al. Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer. Proc Natl Acad Sci USA. 2010;107:246-251.
24. Muller PA, Caswell PT, Doyle B, et al. Mutant p53 drives invasion by promoting integrin recycling. Cell. 2009;139:1327-1341.
25. Ijichi H, Chytil A, Gorska AE, et al. Aggressive pancreatic ductal ade-nocarcinoma in mice caused by pancreas-specific blockade of transforming growth factor-beta signaling in cooperation with active Kras expression. Genes Dev. 2006;20:3147-3160.
26. Izeradjene K, Combs C, Best M, et al. Kras(G12D) and Smad4/Dpc4 haploinsufficiency cooperate to induce mucinous cystic neoplasms and invasive adenocarcinoma of the pancreas. Cancer Cell. 2007;11: 229-243.
27. Collisson EA, Sadanandam A, Olson P, et al. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med. 2011;17:500-503.
28. De La OJ-P, Emerson LL, Goodman JL, et al. Notch and Kras repro-gram pancreatic acinar cells to ductal intraepithelial neoplasia. Proc Natl Acad Sci USA. 2008;105:18907-18912.
29. Wagner M, Greten FR, Weber CK, et al. A murine tumor progression model for pancreatic cancer recapitulating the genetic alterations of the human disease. Genes Dev. 2001;15:286-293.
30. Guerra C, Schuhmacher AJ, Cañamero M, et al. Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-ras oncogenes in adult mice. Cancer Cell. 2007;11:291-302.
31. Morton JP, Jamieson NB, Karim SA, et al. LKB1 haploinsufficiency cooperates with Kras to promote pancreatic cancer through suppression of p21-dependent growth arrest. Gastroenterology. 2010;139:586-597, 597e1-597e6.
32. Skoulidis F, Cassidy LD, Pisupati V, et al. Germline Brca2 heterozygos-ity promotes Kras(G12D)-driven carcinogenesis in a murine model of familial pancreatic cancer. Cancer Cell. 2010;18:499-509.
33. Bardeesy N, Aguirre AJ, Chu GC, et al. Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. Proc Natl Acad Sci USA. 2006;103:5947-5952.
34. Shakya R, Reid LJ, Reczek CR, et al. BRCA1 tumor suppression depends on BRCT phosphoprotein binding, but not its E3 ligase activity. Science. 2011;334:525-528.
35. Rowley M, Ohashi A, Mondal G, et al. Inactivation of Brca2 promotes Trp53-associated but inhibits KrasG12D-dependent pancreatic cancer development in mice. Gastroenterology. 2011;140:1303-1313, e1-e3.
36. Carrière C, Gore AJ, Norris AM, et al. Deletion of Rb accelerates pancreatic carcinogenesis by oncogenic Kras and impairs senescence in premalignant lesions. Gastroenterology. 2011;141:1091-1101.
37. Kojima K, Vickers SM, Adsay NV, et al. Inactivation of Smad4 accelerates Kras(G12D)-mediated pancreatic neoplasia. Cancer Res. 2007; 67:8121-8130.
38. Hezel AF, Gurumurthy S, Granot Z, et al. Pancreatic LKB1 deletion leads to acinar polarity defects and cystic neoplasms. Mol Cell Biol. 2008; 28:2414-2425.
39. Perez-Mancera PA, Rust AG, van der Weyden L, et al. The deubiquiti-nase USP9X suppresses pancreatic ductal adenocarcinoma. Nature. 2012;486:266-270.
40. Heiser PW, Cano DA, Landsman L, et al. Stabilization of beta-catenin induces pancreas tumor formation. Gastroenterology. 2008;135: 1288-1300.
41. Maniati E, Bossard M, Cook N, et al. Crosstalk between the canonical NF-JB and Notch signaling pathways inhibits PparF expression and promotes pancreatic cancer progression in mice. J Clin Invest. 2011; 121:4685-4699.
42. Siveke JT, Einwachter H, Sipos B, et al. Concomitant pancreatic activation of Kras(G12D) and TGFa results in cystic papillary neoplasms reminiscent of human IPMN. Cancer Cell. 2007;12:266-279.
43. Tinder TL, Subramani DB, Basu GD, et al. MUC1 enhances tumor progression and contributes toward immunosuppression in a mouse model of spontaneous pancreatic adenocarcinoma. J Immunol. 2008; 181:3116-3125.
44. Mazur PK, Einwachter H, Lee M, et al. Notch2 is required for progression of pancreatic intraepithelial neoplasia and development of pancreatic ductal adenocarcinoma. Proc Natl Acad Sci USA. 2010; 107:13438-13443.
45. Nolan-Stevaux O, Lau J, Truitt ML, et al. GLI1 is regulated through Smoothened-independent mechanisms in neoplastic pancreatic ducts and mediates PDAC cell survival and transformation. Genes Dev. 2009;23:24-36.
46. Heid I, Lubeseder-Martellato C, Sipos B, et al. Early requirement of Rac1 in a mouse model of pancreatic cancer. Gastroenterology. 2011;141: 719-730, 730e1-730e7.
47. Ying H, Kimmelman AC, Lyssiotis CA, et al. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell. 2012;149:656-670.
48. Collins MA, Bednar F, Zhang Y, et al. Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice. J Clin Invest. 2012;122:639-653.
49. Baines AT, Xu D, Der CJ. Inhibition of Ras for cancer treatment: the search continues. Future Med Chem. 2011;3:1787-1808.
50. Stanger BZ, Stiles B, Lauwers GY, et al. Pten constrains centroacinar cell expansion and malignant transformation in the pancreas. Cancer Cell. 2005;8:185-195.
51. Ying H, Elpek KG, Vinjamoori A, et al. Pten is a major tumor suppressor in pancreatic ductal adenocarcinoma and regulates an NF-JBY cytokinenetwork. Cancer Discov. 2011;1:158-169.
52. Hill R, Calvopina JH, Kim C, et al. PTEN loss accelerates KrasG12D-induced pancreatic cancer development. Cancer Res. 2010;70: 7114-7124.
53. Mann KM, Ward JM, Yew CC, et al. Sleeping Beauty mutagenesis reveals cooperating mutations and pathways in pancreatic adenocarcino-ma. Proc Natl Acad Sci USA. 2012;109:5934-5941.
54. McGrail M, Hatler JM, Kuang X, et al. Somatic mutagenesis with a Sleeping Beauty transposon system leads to solid tumor formation in zebrafish. PLoS One. 2011;6:e18826.
55. Kong B, Michalski CW, Erkan M, et al. From tissue turnover to the cell of origin for pancreatic cancer. Nat Rev Gastroenterol Hepatol. 2011;8:467-472.
56. Murtaugh LC, Kopinke D. Pancreatic stem cells (July 11, 2008), StemBook, ed. The Stem Cell Research Community, StemBook, doi/10.3824/stem-book.1.3.1, http://www.stembook.org.
57. Ku HT. Minireview: pancreatic progenitor cellsVrecent studies. Endocrinology. 2008;149:4312-4316.
58. Gidekel Friedlander SY, Chu GC, Snyder EL, et al. Context-dependent transformation of adult pancreatic cells by oncogenic K-Ras. Cancer Cell. 2009;16:379-389.
59. Morris JP, Cano DA, Sekine S, et al. beta-Catenin blocks Kras-dependent reprogramming of acini into pancreatic cancer precursor lesions in mice. J Clin Invest. 2010;120:508-520.
60. Carrière C, Young AL, Gunn JR, et al. Acute pancreatitis accelerates initiation and progression to pancreatic cancer in mice expressing onco-genic Kras in the nestin cell lineage. PLoS One. 2011;6:e27725.
61. Carrière C, Seeley ES, Goetze T, et al. The Nestin progenitor lineage is the compartment of origin for pancreatic intraepithelial neoplasia. Proc Natl Acad Sci USA. 2007;104:4437-4442.
62. + ductal cells are multip-otent progenitors throughout development but do not produce new endocrine cells in the normal or injured adult pancreas. Development. 2011;138:653-665.
63. Furuyama K, Kawaguchi Y, Akiyama H, et al. Continuous cell supply from a Sox9-expressing progenitor zone in adult liver, exocrine pancreas and intestine. Nat Genet. 2010;43:34-41.
64. Stanger BZ, Dor Y. Dissecting the cellular origins of pancreatic cancer. Cell Cycle. 2006;5:43-46.
65. Kopinke D, Brailsford M, Pan FC, et al. Ongoing Notch signaling maintains phenotypic fidelity in the adult exocrine pancreas. Dev Biol. 2012;362:57-64.
66. Bao B, Wang Z, Ali S, et al. Notch-1 induces epithelial-mesenchymal transition consistent with cancer stem cell phenotype in pancreatic cancer cells. Cancer Lett. 2011;307:26-36.
67. Quante M, Wang TC. Stem cells in gastroenterology and hepatology. Nat Rev Gastroenterol Hepatol. 2009;6:724-737.
68. Clark CE, Hingorani SR, Mick R, et al. Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res. 2007;67:9518-9527.
69. Pylayeva-Gupta Y, Lee KE, Hajdu CH, et al. Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neopla-sia. Cancer Cell. 2012;21:836-847.
70. Bayne LJ, Beatty GL, Jhala N, et al. Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. Cancer Cell. 2012;21:822-835.
71. Olive KP, Jacobetz MA, Davidson CJ, et al. Inhibition of hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science. 2009;324:1457-1461.
72. Thayer SP, di Magliano MP, Heiser PW, et al. Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature. 2003; 425:851-856.
73. Tian H, Callahan CA, DuPree KJ, et al. Hedgehog signaling is restricted to the stromal compartment during pancreatic carcinogenesis. Proc Natl Acad Sci USA. 2009;106:4254-4259.
74. Bailey JM, Mohr AM, Hollingsworth MA. Sonic hedgehog paracrine signaling regulates metastasis and lymphangiogenesis in pancreatic cancer. Oncogene. 2009;28:3513-3525.
75. Bailey JM, Swanson BJ, Hamada T, et al. Sonic hedgehog promotes des-moplasia in pancreatic cancer. Clin Cancer Res. 2008;14:5995-6004.
76. Apelqvist A, Li H, Sommer L, et al. Notch signalling controls pancreatic cell differentiation. Nature. 1999;400:877-881.
77. Miyamoto Y, Maitra A, Ghosh B, et al. Notch mediates TGF alphaYinduced changes in epithelial differentiation during pancreatic tumorigenesis. Cancer Cell. 2003;3:565-576.
78. Ranganathan P, Weaver KL, Capobianco AJ. Notch signalling in solid tumours: a little bit of everything but not all the time. Nat Publish Group. 2011;11:336-351.
79. Cook N, Olive KP, Frese K, et al. K-rasYdriven pancreatic cancer mouse model for anticancer inhibitor analyses. Methods Enzymol. 2008;439: 73-85.
80. Singh M, Lima A, Molina R, et al. Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models. Nat Biotechnol. 2010;28:585-593.
81. Jacobetz MA, Chan DS, Neesse A, et al. Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut. 2012; [Epub ahead of print].
82. Provenzano PP, Cuevas C, Chang AE, et al. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adeno-carcinoma. Cancer Cell. 2012;21:418-429.
83. Frese KK, Neesse A, Cook N, et al. nab-Paclitaxel potentiates gemcita-bine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer. Cancer Discov. 2012;2:260-269.
84. Von Hoff DD, Ramanathan RK, Borad MJ, et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol. 2011;29:4548-4554.
85. Beatty GL, Chiorean EG, Fishman MP, et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science. 2011;331:1612-1616.
86. Ijichi H, Chytil A, Gorska AE, et al. Aggressive pancreatic ductal ade-nocarcinoma in mice caused by pancreas-specific blockade of transforming growth factor-beta signaling in cooperation with active Kras expression. Genes Dev. 2006;20:3147-3160.
87. Feldmann G, Fendrich V, McGovern K, et al. An orally bioavailable small-molecule inhibitor of hedgehog signaling inhibits tumor initiation and metastasis in pancreatic cancer. Molecular Cancer Therapeutics. 2008;7:2725-2735.
88. Solan JL, Hingorani SR, Lampe PD. Changes in connexin43 expression and localization during pancreatic cancer progression. J Membr Biol. 2012;245:255-262.
89. Cook N, Frese KK, Bapiro TE, et al. Gamma secretase inhibition promotes hypoxic necrosis in mouse pancreatic ductal adenocarcinoma. J Exp Med. 2012;209:437-444.
90. Gama Sosa MA, De Gasperi R, Elder GA. Animal transgenesis: an overview. Brain Struct Funct. 2010;214:91-109.
91. Anastassiadis K, Fu J, Patsch C, et al. Dre recombinase, like Cre, is a highly efficient site-specific recombinase in E. coli, mammalian cells and mice. Dis Models Mech. 2009;2:508-515.
92. Mayr U, von Werder A, Seidler B, et al. RCAS-mediated retroviral gene delivery: a versatile tool for the study of gene function in a mouse model of pancreatic cancer. Hum Gene Ther. 2008;19:896-906.
93. Seidler B, Schmidt A, Mayr U, et al. A Cre-loxP-based mouse model for conditional somatic gene expression and knockdown in vivo by using avian retroviral vectors. Proc Natl Acad Sci USA. 2008;105: 10137-10142.
94. Heyer J, Kwong LN, Lowe SW, et al. Non-germline genetically engineered mouse models for translational cancer research. Nature reviews. Cancer. 2010;10:470-480.